Extension Study for 2993-112

NCT01789957 on ClinicalTrials.gov · last registry update 2015-02-24

Finished June 2004, after enrolling 225 people. Primary outcome, as filed: Change in HbA1c from Day 1 of Protocol 2993-112 to Week 52 (or termination). exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 225
Started: 2002-09
Primary completion: 2004-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c from Day 1 of Protocol 2993-112 to Week 52 (or termination)

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.